Investor FAQs

Investor FAQs

Show all

ContraVir was spun-off from Synergy Pharmaceuticals in 2014 through a Securities and Exchange Commission (SEC) Form 10 filing, which is also known as the General Form for Registration of Securities.
ContraVir currently has 19 full-time employees on staff.
ContraVir’s outside legal counsel is Jeffrey J. Fessler, a partner in the Corporate Practice at Sheppard Mullin in New York City.
No, ContraVir does not issue dividends on our common stock.
December 31st.
ContraVir’s transfer agent is Bob Winterle of Philadelphia Stock Transfer. He can be reached at 866-223-0448 or via email at bwinterle@philadelphiastocktransfer.com.
ContraVir’s auditors are BDO USA, LLP.
Stephen Kilmer
Investor Relations
skilmer@contravir.com
(646) 274 3580